Current and Future Challenges for Innovative Biomarker Development

Wednesday 12th April 2017
All day

Royal Society of Medicine, 1 Wimpole Street, London, W1G 0LZ

More about this event

The CM-Path biomarker workshop series aims at discussing the current and future challenges of innovative biomarker developments, and agreeing on the barriers for delivery of clinical diagnostics assays. The first workshop is organized by the CM-Path Discovery Workstream for the following objectives:

Developing an understanding of various research strategies, study design and their practicality for setting up biomarker discovery and development studies
With a special focus on emerging technologies for biomarker research using formalin-fixed paraffin-embedded (FFPE) materials

This event is ceritified for 6 CPD points from the Royal College of Pathologists.

Prices

Consultant-level clinician or scientist – £125
Trainee-level clinician or scientist (including postdocs and PhD students) – £100

Deadline to register is 5PM Thursday 6 April.

» Download the agenda (PDF)

Current and Future Challenges for Innovative Biomarker Development Workshop Review

The CM-Path workshop ‘Current and Future Challenges for Innovative Biomarker Development’ was organised by Dr Maggie Cheang and held on 12 April at the Royal Society of Medicine. The day brought together a number of medical specialities including pathologists, oncologists, statisticians, translational scientists and others. Consumer representatives were also in attendance on the day challenging speakers with new concepts and ideas, and providing a much needed patient perspective.

The day had a special focus on new technologies that can be used on FFPE samples including proteomics, RNA sequencing and DNA analysis. The afternoon highlighted the development of biomarker studies for immuno-oncology approaches. Professor Mitch Dowsett from the Institute of Cancer Research delivered a notable presentation highlighting the lessons learnt from a career delivering pioneering biomarker development studies in breast cancer.

The CM-Path team will now be building a suite of guidance documents to help researchers improve the quality of biomarker development studies in the future. The second CM-Path biomarker workshop in this series is being planned for early 2018, further information will be available in due course.